Sign In
OZYMF.US
id: 735

Orphazyme A/S (ORPH) $2.5M IPO Settlement

N.D. Illinois
Court
1:21-CV-03640
Case number
09/29/2020
Class period Start
11/04/2021
Class period End
01/17/2024
Claim deadline
Orphazyme A/S (ORPH) agreed to settle $2.5 million with investors to end claims over misleading statements during its IPO in 2020.
Case Status
Disbursement
Alleged Offence
Misleading Statements, 
Failure to Disclose, 
Omissions
Suspected Party
Directors, 
Management
Security Type
Depository Securities (ADS, ADR, GDR)
Trade Direction
Long
Payout per Share
0.12
Filing date
07/09/2021
Plaintiffs
Marko Busic
Attorneys
Bronstein, Gewirtz & Grossman, LLC (New York, NY), Pomerantz LLP (Chicago, IL)
Defendants
Christophe Bourdon, Anders Vadsholt, Kim Stratton, Thomas Blaettler, Molly Painter, Georges Gemayel, Bo Jesper Hansen, Martin Bonde, Rémi Droller, Sten Verland, Martijn Kleijwegt, Anders Hedegaard, Catherine Moukheibir, Carrolee Barlow
Judge
Hon. John F. Kness
Administrator
A.B. Data Ltd
Settlement agreement date
2023-05-12
Trades matching type
FIFO
Disbursement date
09/20/2024
+$2,500,000
Cash Settlement Amount

Orphazyme A/S

Strategic Partners A/S does not have significant operations. Previously, it was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was formerl...

    Ticker
    OZYMF.US
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    Visionhouse, Herlev, Denmark, 2730